How many drugs treat Falciparum malaria?

Drug Landscape tracks 10 marketed treatments for Falciparum malaria (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/falciparum-malaria.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Falciparum malaria — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Falciparum malaria (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Falciparum malaria, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Artesunate	ARTESUNATE	Amivas	artesunate		2020-01-01
Coartem	LUMEFANTRINE	Novartis	Antimalarial [EPC]	Potassium voltage-gated channel subfamily H member 2	2009-01-01
Qualaquin	QUININE	Sun Pharm Industries	Antimalarial	Sodium channel alpha subunits; brain (Types I, II, III)	2005-01-01
Malarone	PROGUANIL	GSK	Antimalarial [EPC]		2000-01-01
Halfan	HALOFANTRINE	GSK	Antimalarial	Potassium voltage-gated channel subfamily H member 2	1992-01-01
Azo Gantrisin	sulfafurazole	Alra	Sulfonamide Antimicrobial	Endothelin-1 receptor	1971-01-01
Hydroxychloroquine Sulfate	HYDROXYCHLOROQUINE	Advanz	Antimalarial	Toll-like receptor 9	1955-01-01
Aralen	CHLOROQUINE	Sanofi	Antimalarial	Sigma non-opioid intracellular receptor 1	1949-01-01
Hydroxychloroquin	Hydroxychloroquin	Children's Hospital of Fudan University		Transmembrane protein 97, Alpha-1D adrenergic receptor, Alpha-2A adrenergic receptor
Arsuamoon	Arsuamoon	Pfizer

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 3 drugs in Falciparum malaria
GSK · 2 drugs in Falciparum malaria
Sanofi · 2 drugs in Falciparum malaria
Amivas · 1 drug in Falciparum malaria
Children's Hospital of Fudan University · 1 drug in Falciparum malaria
Advanz · 1 drug in Falciparum malaria
Novartis · 1 drug in Falciparum malaria
Pfizer · 1 drug in Falciparum malaria
Sun Pharm Industries · 1 drug in Falciparum malaria
Alra · 1 drug in Falciparum malaria

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Falciparum malaria:

Cite this brief

Drug Landscape (2026). Falciparum malaria — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/falciparum-malaria. Accessed 2026-06-10.

Falciparum malaria full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing